论文部分内容阅读
近年来,卵泡刺激素(follicle-stimulating hormone,FSH)在骨质疏松中的作用得到了证实。卵泡刺激素受体(FSH receptor,FSHR)在成熟的人破骨细胞及破骨细胞前体即单核细胞表面表达,成为阻断FSH作用的潜在靶点。制备了高滴度的兔抗人FSHR多克隆抗体,采用双侧去卵巢手术方法建立SD(Sprague-Dawley)大鼠骨质疏松症动物模型,观察抗FSHR抗体对大鼠实验骨质疏松症的治疗效果。结果显示,卵巢摘除(ovariectomized,OVX)大鼠经抗FSHR多抗和亮丙瑞林(leuprorelin,LE)治疗两周后,与PBS对照组相比,血清FSH和黄体酮(luteinizing hormone,LH)水平显著降低(P<0.05),而雌二醇(estrogen,E2)水平有一定升高,但结果不显著(P>0.05)。另外,骨组织化学染色显示多抗和LE治疗组大鼠骨小梁数目增加,断裂现象较少。这些结果初步表明,采用抗FSHR抗体对SD大鼠骨质疏松症具有一定的治疗作用。
In recent years, the role of follicle-stimulating hormone (FSH) in osteoporosis has been confirmed. The expression of FSH receptor (FSHR) on the surface of mature human osteoclasts and osteoclast precursors, ie, monocytes, has become a potential target for blocking the action of FSH. High-titer anti-human FSHR polyclonal antibody was prepared and the animal model of SD (Sprague-Dawley) osteoporosis was established by bilateral ovariectomy. The effects of anti-FSHR antibody on experimental osteoporosis treatment effect. The results showed that compared with PBS control group, serum FSH and luteinizing hormone (LH) levels in ovariectomized (OVX) rats after anti-FSHR polyclonal antibody and leuprorelin (LE) (P <0.05), while estrogen (E2) increased to some extent, but the result was not significant (P> 0.05). In addition, bone histochemical staining showed that the number of trabecular in polyclonal and LE treated groups increased, and the fracture phenomenon was less. These results preliminarily show that anti-FSHR antibodies have a therapeutic effect on osteoporosis in SD rats.